title: [Intraperitoneal (i.p.) chemotherapy in the management of ovarian cancer--pharmacokinetics and methods of sequential i.p. chemotherapy].
abstract: We studied the systemic efficacy of intraperitoneal (i.p.) chemotherapy which has been used as a locoregional chemotherapy for ovarian cancer. The following results were obtained. 1) The CDDP-based i.v. and i.p. regimen obtained a 90% response rate for ascites and a 35% response rate for measurable lesions. 2) According to the pharmacokinetic analysis of i.p.-chemotherapy, BH-AC showed a regional advantage because of a high AUC-ratio. Meanwhile CDDP and etoposide demonstrated a low AUC-ratio, that has direct effects in the abdominal cavity and anti-tumor effects from the vascular side of the tumor. 3) We performed sequential i.p.-chemotherapy using three types of drainage tubes according to the stage and the size of the residual tumor at operation. The abdomino-centesis using a peel-away introducer for the poor risk patients was very easy and this method could carry out sequential CDDP-i.p.. No patients had signs or symptoms of chemical peritonitis. 4) On the base of these date, we have designed a protocol of i.p. chemotherapy for patients with ovarian cancer.
authors.affiliation: Dept. of Obstetrics and Gynecology, Higasiosaka Central Municipal Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Noda
authors.forename: S
authors.initials: S
authors.lastname: Adachi
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: C
authors.initials: C
authors.lastname: Hirooka
authors.forename: Y
authors.initials: Y
authors.lastname: Kiyozuka
authors.forename: S
authors.initials: S
authors.lastname: Adachi
authors.forename: M
authors.initials: M
authors.lastname: Oku
authors.forename: M
authors.initials: M
authors.lastname: Ichijo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001086:Arabinofuranosyluracil / Q000008:administration & dosage / Q000493:pharmacokinetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003536:Cystadenocarcinoma / Q000188:drug therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000493:pharmacokinetics; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007260:Infusion Pumps; D007263:Infusions, Parenteral; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D013724:Teratoma / Q000188:drug therapy
chemical_list: D003561:Cytarabine; D001086:Arabinofuranosyluracil; D005047:Etoposide; C015019:enocitabine; D002945:Cisplatin